52 related articles for article (PubMed ID: 9461003)
21. Prognostic value of p53 expression in Wilms' tumor in children.
Skotnicka-Klonowicz G; Kobos J; Łoś E; Trejster E; Szymik-Kontorowicz S; Daszkiewicz P
Med Sci Monit; 2001; 7(6):1224-9. PubMed ID: 11687734
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
Cheah PL; Looi LM; Chan LL
Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
Lahoti C; Thorner P; Malkin D; Yeger H
Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
[TBL] [Abstract][Full Text] [Related]
24. p53 mediated tumor cell response to chemotherapeutic DNA damage: a preliminary study in matched pairs of breast cancer biopsies.
Moll UM; Ostermeyer AG; Ahomadegbe JC; Mathieu MC; Riou G
Hum Pathol; 1995 Dec; 26(12):1293-301. PubMed ID: 8522300
[TBL] [Abstract][Full Text] [Related]
25. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.
Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP
Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413
[TBL] [Abstract][Full Text] [Related]
26. Physical and functional interaction between WT1 and p53 proteins.
Maheswaran S; Park S; Bernard A; Morris JF; Rauscher FJ; Hill DE; Haber DA
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5100-4. PubMed ID: 8389468
[TBL] [Abstract][Full Text] [Related]
27. The p53-mdm-2 autoregulatory feedback loop.
Wu X; Bayle JH; Olson D; Levine AJ
Genes Dev; 1993 Jul; 7(7A):1126-32. PubMed ID: 8319905
[TBL] [Abstract][Full Text] [Related]
28. On the expression of the p53 protein in human cancer.
Lane DP
Mol Biol Rep; 1994 Jan; 19(1):23-9. PubMed ID: 8170465
[No Abstract] [Full Text] [Related]
29. Gain of function mutations in p53.
Dittmer D; Pati S; Zambetti G; Chu S; Teresky AK; Moore M; Finlay C; Levine AJ
Nat Genet; 1993 May; 4(1):42-6. PubMed ID: 8099841
[TBL] [Abstract][Full Text] [Related]
30. Molecular and cellular heterogeneity of Wilms' tumor.
Velasco S; D'Amico D; Schneider NR; Timmons C; Chappell E; Lee D; Nisen PD
Int J Cancer; 1993 Feb; 53(4):672-9. PubMed ID: 8094715
[TBL] [Abstract][Full Text] [Related]
31. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations.
Bardeesy N; Falkoff D; Petruzzi MJ; Nowak N; Zabel B; Adam M; Aguiar MC; Grundy P; Shows T; Pelletier J
Nat Genet; 1994 May; 7(1):91-7. PubMed ID: 8075648
[TBL] [Abstract][Full Text] [Related]
32. The yin and yang of p53 in cellular proliferation.
Deppert W
Semin Cancer Biol; 1994 Jun; 5(3):187-202. PubMed ID: 7948947
[TBL] [Abstract][Full Text] [Related]
33. Wilms' tumor and other renal tumors of childhood: a selective review from the National Wilms' Tumor Study Pathology Center.
Beckwith JB
Hum Pathol; 1983 Jun; 14(6):481-92. PubMed ID: 6303938
[TBL] [Abstract][Full Text] [Related]
34. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center.
Zuppan CW; Beckwith JB; Luckey DW
Hum Pathol; 1988 Oct; 19(10):1199-209. PubMed ID: 2844645
[TBL] [Abstract][Full Text] [Related]
35. The p53 tumour suppressor gene.
Levine AJ; Momand J; Finlay CA
Nature; 1991 Jun; 351(6326):453-6. PubMed ID: 2046748
[TBL] [Abstract][Full Text] [Related]
36. Amplification of a gene encoding a p53-associated protein in human sarcomas.
Oliner JD; Kinzler KW; Meltzer PS; George DL; Vogelstein B
Nature; 1992 Jul; 358(6381):80-3. PubMed ID: 1614537
[TBL] [Abstract][Full Text] [Related]
37. The p53 tumor-suppressor gene.
Levine AJ
N Engl J Med; 1992 May; 326(20):1350-2. PubMed ID: 1565147
[No Abstract] [Full Text] [Related]
38. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.
Yew PR; Berk AJ
Nature; 1992 May; 357(6373):82-5. PubMed ID: 1533443
[TBL] [Abstract][Full Text] [Related]
39. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.
Mietz JA; Unger T; Huibregtse JM; Howley PM
EMBO J; 1992 Dec; 11(13):5013-20. PubMed ID: 1464323
[TBL] [Abstract][Full Text] [Related]
40. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.
Kastan MB; Zhan Q; el-Deiry WS; Carrier F; Jacks T; Walsh WV; Plunkett BS; Vogelstein B; Fornace AJ
Cell; 1992 Nov; 71(4):587-97. PubMed ID: 1423616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
